Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Epistem Announces Evaluation of Genedrive® for Pathogen Detection

Published: Thursday, January 16, 2014
Last Updated: Thursday, January 16, 2014
Bookmark and Share
Epistem in cooperative agreement with the US Air Force and with Johns Hopkins University.

Epistem Holdings Plc has announced that it has entered into a cooperative agreement with the US Air Force alongside an agreement with Johns Hopkins University (Advanced Physics Laboratory), to undertake the combat evaluation of Epistem's Genedrive® handheld molecular device for pathogen detection.

The agreement will commence immediately and provides $0.6m (GBP 0.4m) over 5 months to develop and evaluate Genedrive® for the identification of three known disease pathogens.

Successful completion of the combat evaluation programme will secure ongoing investment for the development of Genedrive® as a handheld pathogen detection unit for the US Department of Defence.

Preparations for the 2014 launch of the company's first Genedrive® disease test in Tuberculosis continue, with progress to resolve the earlier reported software and firmware issues now nearing completion.

Whilst unit testing is ongoing, preparations are being made for the commencement of final stage clinical trials in support of Indian regulatory approval.

2014 plans to undertake clinical trials with the Foundation for Innovative New Diagnostics (FIND) have also commenced as a forerunner to a potential WHO recommendation in 2015.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Epistem and CRT Announce Agreement
Agreement for the use of patient derived leukemic Primagraft samples.
Friday, May 01, 2015
Epistem Announces the Successful Evaluation of New RNA-AMP™ Technology
A highly sensitive and reproducible method to derive cDNA from picogram to nanogram quantities of RNA.
Friday, February 13, 2015
Epistem, Global Health Investment Fund Sign Collaborative Funding Agreement
Agreement will see GHIF support the roll-out of Epistem's Genedrive® molecular diagnostic platform.
Wednesday, July 23, 2014
Epistem Announces Further Partnership With The University of Manchester
Partnership will allow the Company to expand its existing range of wound healing models.
Tuesday, April 22, 2014
Epistem Announces Opening of US Laboratory
Laboratory will support the expansion of Epistem's contract research division.
Thursday, March 06, 2014
Epistem Announces Executive Board Appointments
Dr Allan Brown joins the Board as Chief Operating Officer of the Diagnostics division of the Company, with effect from 1st February, 2014.
Monday, January 27, 2014
UK-Norwegian Collaboration Aims to Develop a New Living Skin Equivalent Model
New in vitro human living skin equivalent model for testing inflammatory responses.
Tuesday, May 21, 2013
Epistem Tuberculosis Test Gains CE-IVD Registration
Epistem to place its TB test and Genedrive™ units for sale in the EEA member state markets.
Thursday, July 05, 2012
Epistem Announces Collaboration with GSK
Three year biomarker collaboration in the field of fibrosis research.
Wednesday, March 14, 2012
Epistem Signs Tuberculosis Channel Partner Agreement
Company signs sales and marketing agreement for rapid molecular test for TB.
Tuesday, March 06, 2012
Epistem Holdings Announce £2.8 Million Cash Placing
Company to use the net proceeds to accelerate the development and commercialization of Genedrive™.
Tuesday, November 29, 2011
Epistem Announces Partnership with The University of Manchester
Partnership will allow Epistem to expand its wound healing models range.
Monday, November 14, 2011
Epistem Announces Collaboration With Sanofi-Aventis
3 year collaboration to provide discovery through to clinical biomarker support to oncology programmes of sanofi-aventis and its affiliates.
Monday, March 21, 2011
Epistem Presents its new Ex Vivo Plucked Hair Biomarker Assay at EORTC-NCI-AACR Symposium
New method for maintaining plucked human hairs ex vivo, and treating with therapeutic agents to obtain information on the cellular response to drug treatment.
Friday, November 19, 2010
EpiStem Awarded Further Long Term Funding for NIH Biodefence Programme
The Company has been reappointed for up to five years to provide preclinical testing services as a subcontractor.
Wednesday, November 10, 2010
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos